Evolus Inc (EOLS)vsTeva Pharma Industries Ltd ADR (TEVA)
EOLS
Evolus Inc
$6.67
+1.06%
HEALTHCARE · Cap: $439.25M
TEVA
Teva Pharma Industries Ltd ADR
$34.43
-2.76%
HEALTHCARE · Cap: $40.32B
Smart Verdict
WallStSmart Research — data-driven comparison
Teva Pharma Industries Ltd ADR generates 5649% more annual revenue ($17.35B vs $301.79M). TEVA leads profitability with a 9.0% profit margin vs -14.4%. TEVA earns a higher WallStSmart Score of 66/100 (B-).
EOLS
Avoid30
out of 100
Grade: F
TEVA
Strong Buy66
out of 100
Grade: B-
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+71.0%
Fair Value
$14.83
Current Price
$6.67
$8.16 discount
Intrinsic value data unavailable for TEVA.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Conservative balance sheet, low leverage
Earnings expanding 72.2% YoY
Growing faster than its price suggests
Areas to Watch
0.0% earnings growth
Smaller company, higher risk/reward
Weak financial health signals
ROE of -18730.0% — below average capital efficiency
Moderate valuation
2.3% revenue growth
Negative free cash flow — burning cash
Distress zone — elevated risk
Comparative Analysis Report
WallStSmart ResearchBull Case : EOLS
The strongest argument for EOLS centers on Debt/Equity.
Bull Case : TEVA
The strongest argument for TEVA centers on EPS Growth, PEG Ratio. PEG of 0.85 suggests the stock is reasonably priced for its growth.
Bear Case : EOLS
The primary concerns for EOLS are EPS Growth, Market Cap, Piotroski F-Score.
Bear Case : TEVA
The primary concerns for TEVA are P/E Ratio, Revenue Growth, Free Cash Flow. Debt-to-equity of 2.05 is elevated, increasing financial risk.
Key Dynamics to Monitor
EOLS profiles as a turnaround stock while TEVA is a value play — different risk/reward profiles.
EOLS carries more volatility with a beta of 1.33 — expect wider price swings.
EOLS is growing revenue faster at 6.7% — sustainability is the question.
EOLS generates stronger free cash flow (-10M), providing more financial flexibility.
Bottom Line
TEVA scores higher overall (66/100 vs 30/100). EOLS offers better value entry with a 71.0% margin of safety. Both earn "Strong Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Evolus Inc
HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA
Evolus, Inc., a high-performance beauty company, provides aesthetic medical products for physicians and their patients in the United States. The company is headquartered in Newport Beach, California.
Teva Pharma Industries Ltd ADR
HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA
Teva Pharmaceutical Industries Limited, a pharmaceutical company, develops, manufactures, markets, and distributes generic drugs, specialty drugs, and biopharmaceuticals in North America, Europe, and internationally. The company is headquartered in Petach Tikva, Israel.
Compare with Other DRUG MANUFACTURERS - SPECIALTY & GENERIC Stocks
Want to dig deeper into these stocks?